The RAS/mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathways are frequently activated in UPS, contributing to tumor progression and poor prognosis [63]. Here, MTOR is linked to neoplasm.